NCT04974827

A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer

A Single-arm, Multi-center Phase II Clinical Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer Who Had Recurrence of the Pelvic Wall After Surgery ± Abdominal Aortic Lymph Node Metastasis

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 46 (estimated)
• Sponsor: Hunan Cancer Hospital · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this single-arm study, patient with cervical cancer who had recurrence of the pelvic wall after surgery ± Abdominal aortic lymph node metastasis will be included to evaluate the efficacy and safety of camrelizumab combined with concurrent chemoradiation and subsequent maintenance therapy

Detailed description

The patient received neoadjuvant therapy once every three weeks for a total of seventeen cycles. From the first day of treatment, the patient will undergo concurrent chemoradiation for 5 weeks.The chemotherapy drug is cisplatin or carboplatin every week for 5 weeks. After the end of concurrent chemoradiation, the patient will continue to use camrelizumab as maintenance therapy until one year.

Conditions

• Cervical Cancer

Interventions

Type	Name	Description
DRUG	Camrelizumab	200mg/3weeks
DRUG	Cisplatin or Carboplatin	Cisplatin (40mg/m²), every week Carboplatin(AUC 2)

Timeline

• Start date: 2021-05-20
• Primary completion: 2023-05-20
• Completion: 2023-05-20
• First posted: 2021-07-23
• Last updated: 2021-08-10

Locations

1 site across 1 country: China